C
Chengdu Lingtai Krypton Biotechnology
LncRNA-based therapies for traditionally undruggable targets
About Chengdu Lingtai Krypton Biotechnology
Chengdu Lingtai Krypton Biotechnology (lncTAC), founded in 2021, is a clinical-stage biotechnology company focused on developing innovative nucleic acid drugs based on long non-coding RNA (lncRNA). The company's name, lncTAC, is an acronym for its core "lncRNA-based Targeting Chimera" technology platform.
The founding team combines deep scientific expertise with extensive pharmaceutical industry experience. Founder and Chairman, Professor Xu Song, is a pioneering scientist in the lncRNA field with 20 years of research experience, a PhD from Peking Union Medical College, and postdoctoral work at Yale University. He is joined by co-founder and CEO, Dr. Lihua Ding, who brings over 30 years of senior management experience from multinational and domestic pharmaceutical companies, and co-founder Professor Chong Qin, an expert in PROTAC and one of the inventors of the lncTAC® technology.
The company has developed two core proprietary technology platforms: lncTAC® and UNAST®. The lncTAC® platform utilizes lncRNA-mediated targeting chimera technology to address previously "undruggable" targets. The UNAST® platform was created to solve the critical challenges of nucleic acid drug instability and delivery. Together, these platforms form the foundation for a rich pipeline of over 20 innovative products. These drug candidates target a range of refractory diseases, including cardiovascular and cerebrovascular diseases, neurodegenerative conditions like Alzheimer's and Parkinson's, and various cancers such as pancreatic, lung, and colorectal cancer.
LncTAC's business model focuses on research and development, with a commercialization strategy centered on out-licensing and forming in-depth collaborations with domestic and multinational corporations for market development. The company has successfully raised significant capital, including a Pre-A round of ¥100 million in August 2023, to advance its pipeline through preclinical stages and expand its research teams.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jun 2026 | — | — | Legend Capital · Pan-Lin Asset Management · River Head Capital · Beijing Huafang Investment | ↗ |
| SEED✓Equity / VC | Oct 2023 | $14M | $55M | Legend Capital · China Medical System Holdings · Guosheng Capital · Firefly Haoyue | ↗ |
Growth signals
Latest recorded traffic for Chengdu Lingtai Krypton Biotechnology is 530 monthly website visits, up 253.3% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Chengdu Lingtai Krypton Biotechnology in its local ecosystem
The Chengdu Lingtai Krypton Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Legend Capital
China Medical System Holdings- GCGuosheng Capital
- FHFirefly Haoyue
Series A4 investors entered at this stage
Pan-Lin Asset Management
River Head Capital- BIBeijing Huafang Investment
- ITIMEIK Technology
Other known investors1 additional known investor
Bayer Co.Lab
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Chengdu Lingtai Krypton Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Chengdu Lingtai Krypton Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









